Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT

TP53 gene alteration confers inferior prognosis in refractory/relapse aggressive B-cell non-Hodgkin lymphoma (r/r B-NHL). From September 2016 to September 2020, 257 r/r B-NHL patients were assessed for eligibility for two trials in our center, assessing anti-CD19 and anti-CD22 chimeric antigen recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Jia, Xiao, Min, Mao, Zekai, Wang, Na, Cao, Yang, Xiao, Yi, Meng, Fankai, Sun, Weimin, Wang, Ying, Yang, Xingcheng, Chen, Liting, Zhang, Yicheng, Zhu, Haichuan, Zhang, Shangkun, Zhang, Tongcun, Zhou, Jianfeng, Huang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995369/
https://www.ncbi.nlm.nih.gov/pubmed/35399106
http://dx.doi.org/10.1038/s41392-022-00924-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995369/
https://www.ncbi.nlm.nih.gov/pubmed/35399106
http://dx.doi.org/10.1038/s41392-022-00924-0

Ejemplares similares